Formulation Development

DRUG DELIVERY – A Topical Tacrolimus Microemulsion for Plaque-Type Psoriasis Therapy

Johannes Wohlrab, MD; Alexandra Goebel, PhD; Dieter Scherer, PhD; Debra Bingham, and Reinhard H.H. Neubert, PhD, develop a colloidal preparation, a microemulsion, that meets the specific conditions for penetration of the psoriatic skin and achieves the required bioavailability of the drug in the underlying tissue, which cannot be achieved by conventional formulations.

FORMULATION DEVELOPMENT – Next-Generation PEGylation Enables Reduced Immunoreactivity of PEG-Protein Conjugates

Merry R. Sherman, PhD; Mark G.P. Saifer, PhD; L. David Williams, PhD; Shawnya J. Michaels, MS; and Monika A. Sobczyk, MS; illustrate the close parallels between the results of Armstrong et al with respect to anti-PEG antibodies detected in sera of ALL patients treated with mPEG-asparaginase and the results reported by Sundy et al based on the Phase III clinical trials of mPEG-uricase in patients with RCG



CURE Pharmaceutical to Acquire Chemistry Holdings Inc.

CURE Pharmaceutical, an innovative drug delivery and development company, recently announced that it has agreed to acquire Chemistry Holdings Inc., a formulation technology company that is developing innovative delivery systems for a variety of industries, in an all-stock transaction.